Target Cancer Genomic Profiling Service

ACTDrug®+ : Select Drugs for Your Cancer Patient

Providing tailored drug options through precise genomic profiling for 40 druggable genes

A Precise Choice for Cancer Genomic Profiling

ACTDrug®+ is a next-generation sequencing based assay, sequencing 40 druggable genes simultaneously from cancer specimens in our CAP accredited lab. This assay is specially designed for patients with breast cancer, lung, colorectal or gastric cancer, providing tailored genomic profile and recommendations of targeted drugs approved by U.S. FDA.

Exploring Various Genetic Alterations for More Precise Therapeutic Implications

ACTDrug®+ sequences 40 druggable genes and performs various genetic variation analysis. Besides single nucleotide variation (SNV) and small insertion/ deletion (InDel), it provides copy number variation (CNV) analysis for 22 genes to detect more drug related important alterations and provide more precise implications.


ACTDrug®Hallmark of ACTDrug

  1. For All Solid Tumors

    Select suitable treatment for newly diagnosed patients based on druggable genetic mutations
  2. Precise Report Content

    Targeted therapy and hormonal therapy approved by U.S. FDA or in clinical trials

Why ACTDrug®+

Can be performed Fast and Accurately

  1. Drug Targeted-Based Panel

    Sequencing 40 druggable genes with genetic alterations
  2. Offering Tailored Drug Options

    Analyzing single nucleotide variation (SNV), small insertion/deletion (InDel) and copy number variation (CNV) to provide tailored drug options
  3. Short Turnaround Time

    Providing professional solutions within 12 calendar days
  4. High Sensitivity

    Using NGS platform for microscale specimens
  5. Pioneering Bioinformatics

    Specializing in cancer biology, medical biology, molecular biology, cell biology, immunology, bioinformatics, data science,and pharmaceutical biology to provide insightful interpretation


Next Generation Sequencing

40 druggable  genes


> 3800

Sequencing Mean Depth

>800 X


Comprehensive testing of

31 fusion genes and 182 fusion 


Sample Types


.5-20 unstained sections (10µm/slide)

.1H&E stained slide (5µm)

*Cell block from pleural effusion, ascites or pericardial hydrops (≥1X106cells)

*Pleural effusion, ascties or pericardial hydrops  need to be processed into cell blocks before sending to ACT Genomics.